RCT of quadrivalent HPV vaccine demonstrates protection against the development of anogenital warts in young men

posted 11 Feb 2011, 13:52 by Damian Wood   [ updated 13 Oct 2012, 11:07 ]
A double blind placebo controlled RCT of 3 does of quadrivalent HPV vaccine in 4065 males aged 16-26yrs from 18 countries showed an efficacy of 65% (intention to treat) and 90% (per-protocol) in preventing external anogenital lesions secondary to HPV subtypes 6,11,16 or 18. This study published by Guiliano et al in the NEJM again raises the question as to whether young men shold be included in HPV immunisation strategies.